SIGLEC15 expression suppresses EMT and metastatic capacity in breast cancer. (IMAGE)
Caption
(A) Pathway score test analysis for malignant cells between SHES and SLES. (B) Pathway score test analysis for mesenchymal cells between SHES and SLES. (C) Cytometry Trace (Cytotrace) analysis showed the differential power of cells in BRCA bone metastasis from the GSE190772 dataset. (left) Differential power of the cells(right). Subcluster of malignant cells in BRCA bone metastasis. (D) Differential trajectories of malignant cells calculated via monocle3. (E) The difference test of cell proportions of malignant cell subclusters in different groups depend on R-package scProportionTest. (F) The EMT pathway score test analysis for malignant cell subclusters in BRCA bone metastasis from the GSE190772 dataset calculated by AUCell. (G) Western blot analysis detected changes in EMT-related protein levels in SIGLEC15-overexpressing BT549 and MB231 cells. (H) Transwell assays examined changes in the migration and invasion of SIGLEC15-overexpressing BT549 and MB231 cells. Quantitative analysis of the results was performed. (I) Quantitative analysis for the wound-healing test results. * P ≤ 0.05. ** P ≤ 0.01. *** P ≤ 0.001.
Credit
ZhaoFu Tan, Hongbin Xin, Jian Chen, Ming Lei, Gang Tu, Lingfeng Tang
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND